Cipla

Which are the latest news on Cipla?

Why is Cipla Ltd. falling/rising?

As of 05-Sep, Cipla Ltd. is experiencing a stock price decline to 1,385.00, down -0.29%, following a three-day downward trend and a total weekly decline of -2.33%. Contributing factors include trading below moving averages, reduced investor participation, negative financial results over recent quarters, and underperformance against market benchmarks.

As of 05-Sep, Cipla Ltd. is experiencing a decline in its stock price, currently at 1,385.00, reflecting a change of -4.0 (-0.29%). The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -2.33% over the past week. This performance is in line with the broader market, as the Sensex has also decreased by -0.97% during the same period.<BR><BR>Several factors contribute to the stock's decline. Firstly, Cipla is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, there has been a notable drop in investor participation, with the delivery volume on September 3 falling by -21.45% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>Financially, the company has reported negative results for the last three consecutive quarters, with a significant decline in profits, as evidenced by a -45.53% growth in PAT over the past nine months. Furthermore, the stock has underperformed against benchmarks, generating -12.21% returns over the last year, which is worse than the -5.21% decline of the BSE500 index. This consistent underperformance, coupled with poor long-term growth prospects—evidenced by an annual operating profit growth rate of only 2.94% over the last five years—has led to a negative sentiment surrounding the stock.<BR><BR>While Cipla is net-debt free and has high institutional holdings, these factors have not been sufficient to offset the negative trends in performance and investor sentiment. Overall, the combination of declining stock performance, poor financial results, and reduced investor engagement are key reasons for the current fall in Cipla Ltd.'s stock price.

Should I buy, sell or hold Cipla Ltd.?

Who are in the management team of Cipla?

Cipla's management team includes key members such as Y K Hamied (Chairman), Umang Vohra (Managing Director & Global CEO), and several independent directors like Ashok Sinha and Peter Mugyenyi, who collectively guide the company's strategic direction and operations.

The management team of Cipla includes the following key members:<BR><BR>1. **Y K Hamied** - Chairman (Non-Executive)<BR>2. **M K Hamied** - Vice Chairman<BR>3. **S Radhakrishnan** - Non-Executive & Non-Independent Director<BR>4. **Ashok Sinha** - Non-Executive & Independent Director<BR>5. **Peter Mugyenyi** - Non-Executive & Independent Director<BR>6. **Adil Zainulbhai** - Non-Executive & Independent Director<BR>7. **Punita Lal** - Non-Executive & Independent Director<BR>8. **Samina Hamied** - Executive Vice Chairperson<BR>9. **Umang Vohra** - Managing Director & Global CEO<BR>10. **Rajendra Chopra** - Company Secretary & Compliance Officer<BR>11. **Robert A Stewart** - Independent Director<BR>12. **P R Ramesh** - Independent Director<BR>13. **Mandar Purushottam Vaidya** - Independent Director<BR><BR>This team plays a crucial role in guiding Cipla's strategic direction and operations.

What does Cipla do?

Cipla Limited is a leading Indian pharmaceutical company that manufactures and markets a variety of branded and generic drugs and Active Pharmaceutical Ingredients (APIs). As of June 2026, it reported net sales of ₹7,119 Cr and a net profit of ₹789 Cr, with a market capitalization of ₹114,373 Cr.

Overview: <BR>Cipla Limited is one of the leading pharmaceutical companies in India, engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Cipla was incorporated in the year 1935. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7,119 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 789 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 114,373 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.92% <BR>Debt-Equity: -0.24 <BR>Return on Equity: 11.87% <BR>Price to Book: 3.33 <BR><BR>Contact Details: <BR>Address: Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-24826000 <BR>Email: cosecretary@cipla.com <BR>Website: http://www.cipla.com

Who are the peers of the Cipla?

Cipla's peers include Sun Pharma, Divi's Lab, Torrent Pharma, Zydus Lifesci, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma. Cipla shows below-average growth and the lowest 1-year return among its peers at -10.92%.

Peers: Cipla's peers include Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Zydus Lifesci., Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, and Glenmark Pharma, while Average management risk is found at Aurobindo Pharma. Growth ratings show that excellent growth is seen at Sun Pharma.Inds., Zydus Lifesci., and Lupin, while below average growth is noted at Cipla, Divi's Lab., Laurus Labs, and Aurobindo Pharma, and the rest have average or good growth. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Zydus Lifesci., Cipla, Mankind Pharma, and Aurobindo Pharma, while good capital structure is found at Torrent Pharma, Lupin, and Glenmark Pharma, and average capital structure is noted at Laurus Labs.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 122.69%, while Cipla has the lowest at -10.92%, indicating that Cipla's performance is significantly below its peers. Additionally, Dr Reddy's Labs and Lupin have negative six-month returns.

How big is Cipla?

As of 31st August, Cipla Ltd. has a market capitalization of 114,373.00 Cr, with recent net sales of 28,324.40 Cr and a net profit of 3,370.66 Cr.

As of 31st August, Cipla Ltd. has a market capitalization of 114,373.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Cipla reported Net Sales of 28,324.40 Cr and a Net Profit of 3,370.66 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 34,431.95 Cr and Total Assets of 41,594.96 Cr.

Are Cipla Ltd. latest results good or bad?

Cipla Ltd.'s latest results show modest revenue growth of 2.33% year-on-year but a significant net profit decline of 39.19%, raising concerns about operational efficiency and margin compression. While revenue recovery is positive, the drop in profitability suggests challenges ahead for the company.

Cipla Ltd.'s latest results present a mixed picture. On one hand, the company reported a revenue of ₹7,119.28 crore for Q1 FY27, which reflects a modest year-on-year growth of 2.33% and a significant sequential increase of 8.84%. This indicates a recovery in demand after two quarters of decline.<BR><BR>However, the net profit of ₹789.05 crore represents a sharp decline of 39.19% year-on-year, although it shows a strong recovery of 42.26% compared to the previous quarter. The operating margin, which stands at 16.85%, has decreased significantly from 26.01% in the same quarter last year, indicating ongoing challenges in cost management and pricing power.<BR><BR>Overall, while revenue growth is a positive sign, the substantial drop in profitability and margin compression raises concerns about the company's operational efficiency and ability to sustain growth in a competitive market. Investors may view this as a critical juncture for Cipla, where management's focus on reversing margin pressures will be essential for restoring confidence and profitability.

Is Cipla technically bullish or bearish?

As of December 1, 2025, Cipla's technical trend has shifted to sideways, with mixed indicators showing a mildly bearish MACD, bullish weekly RSI, and conflicting signals from moving averages and Bollinger Bands, indicating a lack of clear direction.

As of 1 December 2025, the technical trend for Cipla has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The MACD is mildly bearish on both the weekly and monthly time frames, while the RSI shows bullish momentum on the weekly but no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, contrasting with the bearish signals from Bollinger Bands and KST on the weekly. Dow Theory reflects a mildly bearish stance on the weekly and no trend on the monthly. Overall, the mixed signals suggest a lack of clear direction, reinforcing the sideways trend.

How has been the historical performance of Cipla?

Cipla has demonstrated strong financial growth, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, and profit after tax rising from 1,546.98 Cr to 5,291.05 Cr during the same period. Key metrics such as operating profit and earnings per share also showed significant improvement, reflecting robust profitability and operational efficiency.

Answer:<BR>Cipla has shown a consistent growth trajectory in its financial performance over the years, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25. The total operating income followed a similar upward trend, reaching 27,547.62 Cr in Mar'25 from 19,159.59 Cr in Mar'21. The operating profit (PBDIT) also saw significant growth, climbing to 7,989.77 Cr in Mar'25 from 3,550.19 Cr in Mar'20. Profit before tax rose to 6,820.81 Cr in Mar'25, up from 2,178.18 Cr in Mar'20, while profit after tax reached 5,291.05 Cr in Mar'25, compared to 1,546.98 Cr in Mar'20. The earnings per share (EPS) improved markedly, standing at 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet side, total assets increased from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities also rising from 23,422.79 Cr to 36,742.17 Cr during the same period. Shareholder's funds grew from 15,763.00 Cr in Mar'20 to 31,193.45 Cr in Mar'25, indicating a strengthening equity position. The cash flow from operating activities improved to 5,004.00 Cr in Mar'25 from 3,068.00 Cr in Mar'20, while net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative outflows in previous years. Overall, Cipla's financial metrics reflect a robust growth pattern and improved profitability over the analyzed period. <BR><BR>Breakdown:<BR>Cipla's financial performance has demonstrated a strong upward trend across multiple key metrics. Net sales surged from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, while total operating income mirrored this growth, reaching the same figure in Mar'25. Operating profit (PBDIT) rose significantly from 3,550.19 Cr in Mar'20 to 7,989.77 Cr in Mar'25, showcasing improved operational efficiency. Profit before tax increased from 2,178.18 Cr in Mar'20 to 6,820.81 Cr in Mar'25, and profit after tax followed suit, climbing to 5,291.05 Cr from 1,546.98 Cr in Mar'20. The earnings per share (EPS) also saw a remarkable rise, reaching 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet, total assets grew from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities increasing in tandem. Shareholder's funds strengthened significantly, rising from 15,763.00 Cr to 31,193.45 Cr over the same period. Cash flow from operating activities improved to 5,004.00 Cr in Mar'25, compared to 3,068.00 Cr in Mar'20, and net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative figures in prior years. This overall performance indicates a solid growth trajectory and enhanced profitability for Cipla.

Is Cipla overvalued or undervalued?

As of May 9, 2025, Cipla is considered undervalued with an attractive valuation grade, a PE Ratio of 22.99, and favorable comparisons to peers like Sun Pharma and Divi's Lab, despite recent stock performance lagging behind the Sensex, while showing strong growth potential with a 54.92% return over three years.

As of 9 May 2025, Cipla's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 22.99, an EV to EBITDA of 15.93, and a PEG Ratio of 0.97, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Cipla's valuation appears more appealing, especially when contrasted with Sun Pharma's PE Ratio of 35.25 and Divi's Lab's significantly high PE Ratio of 79.33. Additionally, Dr. Reddy's Labs, which is also rated attractive, has a lower PE Ratio of 19.49, further supporting the notion that Cipla is undervalued in its sector. While Cipla's recent stock performance has lagged behind the Sensex on a year-to-date basis, its strong return over three years at 54.92% reinforces its potential for growth.

Who are the top shareholders of the Cipla?

The top shareholders of Cipla include promoters, with Yusuf Khwaja Hameid holding 18.68%, institutional investors with mutual funds at 20.51% and foreign institutional investors at 26.28%, and individual shareholders who collectively own 14.13%. The largest public shareholder is the HDFC Large and Mid Cap Fund, holding 5.13%.

The top shareholders of Cipla include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Yusuf Khwaja Hameid being the promoter with the highest holding at 18.68%. <BR><BR>In terms of institutional investments, mutual funds hold 20.51% of the shares through 42 schemes, while foreign institutional investors (FIIs) hold 26.28% through 980 different entities. The highest public shareholder is the HDFC Large and Mid Cap Fund, which holds 5.13%. Additionally, individual investors collectively hold 14.13% of the company's shares.

When is the next results date for Cipla?

No Upcoming Board Meetings

What is the bonus history of the Cipla?

Cipla's most recent bonus issue occurred on April 24, 2006, when the company announced a 3:2 bonus, granting shareholders three shares for every two held, with a record date of April 25, 2006.

Cipla has a bonus history that includes a notable issuance on April 24, 2006. During this event, the company announced a 3:2 bonus issue, which means that for every two shares held, shareholders received three shares. The record date for this bonus was April 25, 2006. This was the latest bonus action recorded for Cipla. If you have any more questions about the company or its financials, feel free to ask!

Has Cipla declared dividend?

Cipla Ltd. has declared a 650% dividend, with an ex-date of June 27, 2025. The company has shown strong total returns over various periods, including a 134.92% total return over the past 5 years.

Cipla Ltd. has declared a 650% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 650%<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cipla experienced a price return of 1.37%, with no dividend return, resulting in a total return of 1.37%.<BR><BR>Over the past year, the price return was 1.39%, with a dividend return of 0.85%, leading to a total return of 2.24%.<BR><BR>In the 2-year period, Cipla saw a significant price return of 54.06% and a dividend return of 2.13%, culminating in a total return of 56.19%.<BR><BR>For the 3-year period, the price return was 53.43% with a dividend return of 2.89%, resulting in a total return of 56.32%.<BR><BR>In the last 4 years, the company achieved a price return of 58.24% and a dividend return of 3.27%, leading to a total return of 61.51%.<BR><BR>Over the past 5 years, Cipla reported a remarkable price return of 130.04% along with a dividend return of 4.88%, resulting in a total return of 134.92%.<BR><BR>Overall, Cipla has declared a substantial dividend and has shown strong total returns over various periods, indicating a positive performance trend for the company.